| 0.5834 -0.003 (-0.46%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.76 | 1-year : | 0.89 |
| Resists | First : | 0.65 | Second : | 0.76 |
| Pivot price | 0.54 |
|||
| Supports | First : | 0.54 | Second : | 0.47 |
| MAs | MA(5) : | 0.58 |
MA(20) : | 0.54 |
| MA(100) : | 0.58 |
MA(250) : | 0.53 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.1 |
D(3) : | 62.8 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 0.99 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HBIO ] has closed below upper band by 25.3%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.61 - 0.62 | 0.62 - 0.62 |
| Low: | 0.57 - 0.57 | 0.57 - 0.57 |
| Close: | 0.58 - 0.58 | 0.58 - 0.59 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Tue, 10 Feb 2026
Harvard Bioscience (HBIO) Faces Strategic Evolution in Life Scie - GuruFocus
Tue, 10 Feb 2026
Harvard Bioscience Reports Preliminary Q4 Results and Outlines Growth Strategy for 2026 - Quiver Quantitative
Fri, 30 Jan 2026
What's Going On With Harvard Bioscience Stock Friday? - Harvard Bioscience (NASDAQ:HBIO) - Benzinga
Thu, 29 Jan 2026
Harvard Bioscience Announces Strategic Consolidation of - GlobeNewswire
Thu, 29 Jan 2026
Harvard Bioscience moves manufacturing from Mass. to Minneapolis and Europe - Stock Titan
Wed, 17 Dec 2025
Harvard Bioscience Announces the Successful Completion of - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 45 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 45.8 (%) |
| Shares Short | 435 (K) |
| Shares Short P.Month | 586 (K) |
| EPS | -1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | -61.7 % |
| Operating Margin | 1.1 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | -135.7 % |
| Qtrly Rev. Growth | -6.4 % |
| Gross Profit (p.s.) | 1.11 |
| Sales Per Share | 1.95 |
| EBITDA (p.s.) | 0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 9 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -0.49 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 0.29 |
| Price to Cash Flow | 3.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|